115180.KQ Qurient Co. Ltd
- Market cap
- KRW 654B
- P/E
- -
- P/B
- 38.55x
- ROE
- -236.1%
- Dividend yield
- 0.01%
- Fundamental score
- 0.5/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 115180.KQ undervalued?
Graham numberThe Graham number of Qurient Co. Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Qurient Co. Ltd fundamental analysis
3 of 21 checks passedROE 0/2
Low return on equity (-236.1%), below 10%.
ROA 0/1
Return on assets (-89.2%) is below the industry median (1.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-10.7%) is below the industry median (1.8%).
Revenue Growth 0/2
Revenue shrank 6.2% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 1/2
Moderate debt to equity (77.0%), up to 100%.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.1 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (38.5x) is above the industry median (0.9x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
Dividend yield (0.0%) is in the bottom 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Qurient Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Qurient Co. Ltd
Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company's pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM. Its pipeline products also comprise Adrixetinib (Q702), an…
Full company profileQurient Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Qurient Co. Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | - | - | 4.89B | 8.47B | 9.03B | 9.18B | 6.98B | 7.70B |
| Gross Profit | 0.00 | 0.00 | 0.00 | - | - | 885M | 1.78B | 1.76B | 1.35B | 930M | 764M |
| Operating Income | -11.1B | -12.7B | -16.7B | -23.2B | -21.0B | -24.2B | -27.5B | -23.2B | -27.5B | -29.8B | -41.0B |
| EBITDA | - | - | - | - | - | - | -26.4B | -21.4B | -24.1B | -30.0B | -39.9B |
| Net Income | -10.5B | -12.2B | -16.4B | -22.7B | -20.5B | -22.8B | -25.5B | -21.1B | -23.6B | -30.1B | -40.6B |
| EPS | - | - | - | - | - | -1,708 | -1,389 | -795 | -730 | -808 | -1,091 |
| Balance Sheet | |||||||||||
| Total Assets | 26.2B | 15.7B | 43.2B | 20.5B | 60.8B | 57.6B | 38.4B | 52.5B | 65.6B | 62.0B | 45.6B |
| Total Liabilities | 1.89B | 1.15B | 3.79B | 3.14B | 4.24B | 3.55B | 3.28B | 5.88B | 7.97B | 22.8B | 23.8B |
| Shareholders' Equity | 24.3B | 14.5B | 39.4B | 17.4B | 56.6B | 51.6B | 31.0B | 46.6B | 57.6B | 34.0B | 17.2B |
| Cash & Short-term Investments | 25.7B | 14.9B | 42.3B | 18.8B | 58.7B | 18.5B | 33.1B | 42.8B | 48.2B | 21.0B | 2.34B |
| Total Debt | - | - | - | 461M | 756M | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -9.90B | -12.6B | -13.8B | -24.0B | -19.8B | -24.4B | -25.0B | -22.0B | -23.3B | -28.7B | -36.9B |
| Capital Expenditure | 50.3M | 72.8M | 432M | 12.5M | 10.7M | 260M | 519M | 101M | 83.7M | 3.70B | 60.3M |
| Free Cash Flow | - | - | - | - | - | -24.6B | -25.5B | -22.1B | -23.4B | -32.4B | -36.9B |
| Ratios | |||||||||||
| ROE | -43.3% | -83.9% | -41.7% | -130.6% | -36.2% | -44.3% | -82.2% | -45.3% | -40.9% | -88.3% | -236.1% |
| ROA | -40.2% | -77.8% | -38.0% | -110.6% | -33.7% | -39.7% | -66.3% | -40.2% | -35.9% | -48.5% | -89.2% |
| Net Profit Margin | - | - | - | - | - | -467.6% | -300.6% | -233.8% | -256.7% | -430.4% | -527.7% |
| Debt to Equity | - | - | - | 0.03x | 0.01x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Qurient Co. Ltd dividends
- Dividend yield
- 0.01%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 69.4M | 1.87 | - |
| 2024 | KRW 70.0M | 2.17 | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on Dec 18, 2023.
Who owns Qurient Co. Ltd
- Insiders 25.97%
- Institutions 6.51%
- Public & others 67.52%
- Shares outstanding 39.4M
- Free float 374K
Qurient Co. Ltd company profile
- Company name
- Qurient Co. Ltd
- Ticker
- 115180.KQ
- ISIN
- KR7115180002
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 31
- Fiscal year end
- December
- Address
- C-dong 801, Seongnam-si, South Korea, 13487
- Phone
- 82 31 8060 1600
- Website
- qurient.com
About Qurient Co. Ltd
Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company's pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM. Its pipeline products also comprise Adrixetinib (Q702), an Axl/Mer/CSF1R Inhibitor, which completed phase I for the treatment of solid tumors; and Q901, a selective CDK7 inhibitor, is under Phase I stage for treating solid tumors. The company was formerly known as Quro Science Inc. and changed its name to Qurient Co., Ltd. in October 2011. Qurient Co., Ltd. was founded in 2008 and is headquartered in Seongnam-si, South Korea.
Qurient Co. Ltd management
3- Dr. Ki-Yean NamCEO, CSO & Chairman · born 1971
- Ms. Hyunjin LimSenior Vice President of Management Administration Officer
- Dr. Seung-Joo LeeCSO